Eloxx Pharmaceuticals prices $66.0 million offering, uplists to Nasdaq
Eloxx Pharmaceuticals, Inc. priced a $66.0 million public offering involving common stock and pre-funded warrants, with shares set to trade on Nasdaq starting June 9, 2026. The offering includes 2,975,000 shares at $11.00 each and warrants for 3,025,000 shares at $10.99 each. Leerink Partners and Guggenheim Securities are joint bookrunning managers.
*this image is generated using AI for illustrative purposes only.
Eloxx Pharmaceuticals, Inc. has priced a $66.0 million public offering of common stock and pre-funded warrants to support its uplisting to the Nasdaq Capital Market. The clinical-stage biopharmaceutical company, focused on developing novel small molecule product candidates to treat nonsense mutations, expects gross proceeds of $66.0 million before deducting underwriting discounts and offering expenses. The securities are being offered entirely by Eloxx, with trading scheduled to commence on June 9, 2026, under the symbol "ELOX".
Offering Details
The public offering consists of two primary components. Eloxx is offering 2,975,000 shares of common stock at a public offering price of $11.00 per share. Additionally, the company is offering pre-funded warrants to purchase up to 3,025,000 shares of common stock at a price of $10.99 per pre-funded warrant. This price equals the public offering price per share less the $0.01 per share exercise price of each warrant.
| Security Component | Quantity | Price per Unit |
|---|---|---|
| Common Stock Shares | 2,975,000 | $11.00 |
| Pre-funded Warrants | 3,025,000 | $10.99 |
Transaction Management and Timeline
Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers for the offering, while LifeSci Capital serves as the passive bookrunner. The offering is expected to close on June 10, 2026, subject to customary closing conditions.
A registration statement on Form S-1 (File No. 333-295651) relating to the offering was filed with the Securities and Exchange Commission and became effective on June 8, 2026. The proposed offering is being made only by means of a prospectus.
How does Eloxx Pharmaceuticals plan to allocate the $66.0 million in gross proceeds across its clinical-stage pipeline?
What are the upcoming clinical milestones for the company's nonsense mutation treatments following this capital raise?
How will the uplisting to the Nasdaq Capital Market impact Eloxx's liquidity and institutional investor interest?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
